Cargando…

ACT-6 Clinical manifestations of the patients with relapsed glioblastoma after bevacizumab treatment

Introduction:The outcome of glioblastoma (GBM) is improving recently, but still only temozolomide and bevacizumab (BEV) are recognized as the effective agents that are reimbursed in Japan. On large clinical trials, BEV prolonged progression free survival (PFS) but the remaining survival period from...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kikuchi, Miyu, Takahashi, Masamichi, Yanagisawa, Syunsuke, Ono, Makoto, Miyakita, Yasuji, Tamura, Yukie, Kawauchi, Daisuke, Narita, Yoshitaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8664617/ http://dx.doi.org/10.1093/noajnl/vdab159.036

Ejemplares similares

STMO-17 Treatment outcome of photodynamic therapy using talaporfin sodium for recurrent high-grade glioma
por: Ohno, Makoto, et al.
Publicado: (2021)

Clinical characteristics and prognosis of Glioblastoma patients with infratentorial recurrence
por: Kawauchi, Daisuke, et al.
Publicado: (2023)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

Assessment of therapeutic outcome and role of reirradiation in patients with radiation-induced glioma
por: Ohno, Makoto, et al.
Publicado: (2022)

MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Combination of asleep and awake craniotomy as a novel strategy for resection in patients with butterfly glioblastoma: Two case reports
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Volumetric Analysis of Glioblastoma for Determining Which CpG Sites Should Be Tested by Pyrosequencing to Predict Temozolomide Efficacy
por: Hosoya, Tomohiro, et al.
Publicado: (2022)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Early Diagnosis and Surgical Intervention Within 3 Weeks From Symptom Onset Are Associated With Prolonged Survival of Patients With Glioblastoma
por: Kawauchi, Daisuke, et al.
Publicado: (2022)

RT-5 Boron Neutron Capture Therapy has extended progression-free survival about recurrent malignant peripheral nerve sheath tumor - A case report
por: Watanabe, Yuko, et al.
Publicado: (2021)

Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas
por: Omura, Takaki, et al.
Publicado: (2022)

NQPC-10 END-OF-LIFE PHASE OF GLIOBLASTOMA
por: Omura, Tomoko, et al.
Publicado: (2019)

Bevacizumab for glioblastoma
por: Narita, Yoshitaka
Publicado: (2015)

COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF
por: Omura, Takaki, et al.
Publicado: (2019)

HGG-39. CLINICAL CHARACTERISTICS AND OUTCOME OF PATIENTS WITH RADIATION-INDUCED GLIOMA
por: Ohno, Makoto, et al.
Publicado: (2020)

ACT-02 Changes in Recurrence Pattern and Prognosis of Glioblastoma after Approval of Bevacizumab as First-line Application
por: Funakoshi, Yusuke, et al.
Publicado: (2020)

ACT-03 Clinical outcome and radiological findings of patients with recurrent glioblastomas treated by bevacizumab
por: Handa, Hajime, et al.
Publicado: (2020)

Metformin with Temozolomide for Newly Diagnosed Glioblastoma: Results of Phase I Study and a Brief Review of Relevant Studies
por: Ohno, Makoto, et al.
Publicado: (2022)

ET-05 Alectinib and ceritinib, the second-generation ALK inhibitors, effectively induce glioblastoma cell death
por: Kawauchi, Daisuke, et al.
Publicado: (2020)

ANGI-2 Identification and functions of CD44 as a predictor for bevacizumab-resistant glioblastoma to optimally treat the tumor with bevacizumab
por: Inoue, Akihiro, et al.
Publicado: (2021)

NQPC-13 THE EFFICACY OF RAVEN’S COLORED PROGRESSIVE MATRICES FOR PATIENTS WITH BRAIN TUMOR
por: Yahiro, Sachiko, et al.
Publicado: (2019)

BIMG-06. RESPONSE ASSESSMENT OF BEVACIZUMAB THERAPY FOR GLIOBLASTOMA BY USING MULTIPLE PET TRACERS
por: Miyake, Keisuke, et al.
Publicado: (2021)

TB-4 Antitumor effects of a novel curcumin derivative curcumin monoglucuronide on glioblastoma cells in vitro and in vivo
por: Fujii, Takashi, et al.
Publicado: (2021)

NQPC-10 IMPACT OF HEALTH-RELATED QOL (HRQOL) IN THE FIRST SIX MONTHS AFTER SURGERY ON LONG-TERM POSTOPERATIVE GENERAL HEALTH STATUS IN GLIOMA PATIENTS
por: Kugasawa, Kazuha, et al.
Publicado: (2022)

ML-12 HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANSPLANTATION (HDC-ASCT) FOR THE PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL)
por: Miyakita, Yasuji, et al.
Publicado: (2022)

MET-10 A SINGLE CENTER RETROSPECTIVE ANALYSIS OF AWAKE CRANIOTOMY FOR METASTATIC BRAIN TUMOR
por: Yanagisawa, Shunsuke, et al.
Publicado: (2022)

ANGI-1 Impact of neoadjuvant bevacizumab on transcriptional factor for stemness, macrophage polarization, and oxygenation of tumor microenvironment in glioblastoma
por: Tanaka, Toshihide, et al.
Publicado: (2021)

INTRAVASCULAR LYMPHOMA OF THE CENTRAL NERVOUS SYSTEM PRESENTING AS MULTIPLE CEREBRAL INFARCTIONS
por: MOMOTA, HIROYUKI, et al.
Publicado: (2012)

A retrospective analysis of the prognosis of Japanese patients with sarcoma brain metastasis
por: Toda, Yu, et al.
Publicado: (2023)

NQPC-14 COMPARISON OF QOL SCALES IN PATIENTS WITH BRAIN TUMORS
por: Satomi, Natsuko Tsushita, et al.
Publicado: (2019)

MPC-1 DNA methylome analysis suggested the presence of “true” IDH-wildtype lower-grade gliomas
por: Satomi, Kaishi, et al.
Publicado: (2021)

ACT-3 Reactor-based boron neutron capture therapy with add-on bevacizumab for recurrent malignant glioma: The final report
por: Furuse, Motomasa, et al.
Publicado: (2021)

COT-04 FAMILY SUPPORT FOR PATIENTS WITH PRIMARY MALIGNANT BRAIN TUMORS BY PATIENT SUPPORT GROUP IN NATIONAL CANCER CENTER
por: Horikawa, Mayumi, et al.
Publicado: (2019)

RT-01 Treatment results of salvage gamma knife and bevacizumab (AVAgamma therapy) for recurrent glioblastoma
por: Sato, Kenichi, et al.
Publicado: (2020)

MPC-11 IDH1/2 MUTATIONS ARE ASSOCIATED WITH SEIZURE ONSET AND VETRY IMAGING IN PATIENTS WITH DIFFUSE GLIOMA VISUALIZING 2-HYDROXYGLUTARATE BY MASS SPECTRUM
por: Ohno, Makoto, et al.
Publicado: (2019)

COT-15 LITERATURE REVIEW ON THE DECISION MAKING OF THE BRAIN TUMOR PATIENT
por: Kishi, Tatsuya, et al.
Publicado: (2019)

Assessment of the Diagnostic Utility of Serum MicroRNA Classification in Patients With Diffuse Glioma
por: Ohno, Makoto, et al.
Publicado: (2019)

ACT-16 THE POTENTIAL OF HYPOFRACTIONATED RADIOTHERAPY AND BEVACIZUMAB FOR GLIOBLASTOMA TREATMENT
por: Hata, Nobuhiro, et al.
Publicado: (2019)

COT-11 Administration of Bevacizumab for patients who failed to complete Stupp regimen after glioblastoma surgery
por: Kon, Takashi, et al.
Publicado: (2020)

A rare case of brain metastasis from poorly differentiated small bowel adenocarcinoma
por: Yamazawa, Erika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_dsksi14pe043f26l70s13d24o7